Evaluation of the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in colorectal cancer

Xutai Li,Chen Sun,Rui Xiong,Yutong Wu,Huimei Zhou,Zhenjian Ge,Yingqi Li,Wenkang Chen,Wuping Wang,Pengwu Zhang,Shengjie Lin,Siwei Chen,Wei Li,Guoqing Lv,Ling Ji,Yongqing Lai

DOI: https://doi.org/10.1101/2024.08.20.24312286

2024-10-22

Abstract:Background: Colorectal cancer poses a severe risk to public health and has a substantial financial impact. Tumor markers such as CEA, CA125, CA19-9, and others, as well as the fecal occult blood test (FOBT), are frequently utilized for colorectal cancer screening and initial diagnosis. However, false-positive results of FOBT, CEA, CA125, and CA19-9 can lead to misdiagnosis and wrong colorectaloscopy, while their false-negative results can lead to missed diagnosis and delayed treatment. Finding practical, affordable, and non-invasive diagnostic techniques is crucial to lowering the false-positive and false-negative rates of FOBT and other indicators. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in colorectal cancer. Patients and methods: This study eventually included 916 participants (602 in the malignant group and 314 in the benign group). Serum samples from individuals were obtained and examined using the YiDiXie™ all-cancer detection kit to assess the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively. Results: The sensitivity of YiDiXie™-SS was 99.0% (95% CI: 97.8% - 99.5%) and its specificity was 63.1% (95% CI: 57.6% - 68.2%). This means that YiDiXie™-SS has an extremely high sensitivity and relatively high specificity in colorectal tumors.YiDiXie™-HS has a sensitivity of 93.7% (95% CI: 91.5% - 95.4%) and a specificity of 86.3% (95% CI: 82.1% - 89.7%). This means that YiDiXie™-HS has high sensitivity and specificity in colorectal tumors.YiDiXie™-D has a sensitivity of 82.6% (95% CI: 79.3% - 85.4%) and a specificity of 93.9% (95% CI: 90.7% - 96.1%). This means that YiDiXie™-D has relatively high sensitivity and very high specificity in colorectal tumors. YiDiXie™-SS significantly reduced the false-positive rates of FOBT, CEA, CA125, and CA19-9 with essentially no increase in malignancy leakage. YiDiXie™-HS substantially reduced the false-negative rates of FOBT, CEA, CA125, and CA19-9. YiDiXie™-D significantly reduces the false positive rate of FOBT, CEA, CA125, CA19-9. YiDiXie™-D significantly reduces the false negative rate of FOBT, CEA, CA125, CA19-9 while maintaining a high level of specificity. Conclusion: YiDiXie™-SS has very high sensitivity and relatively high specificity in colorectal tumors.YiDiXie™-HS has high sensitivity and high specificity in colorectal tumors.YiDiXie™-D has relatively high sensitivity and very high specificity in colorectal tumors. YiDiXie™-SS significantly reduced false-positive rates for FOBT, CEA, CA125, and CA19-9 with essentially no increase in delayed treatment for colorectal cancer.YiDiXie™-HS substantially reduced false-negative rates for FOBT, CEA, CA125, and CA19-9. YiDiXie™-D can significantly reduce the false-positive rate of FOBT, CEA, CA125 and CA19-9, or significantly reduce the false-negative rate of FOBT, CEA, CA125 and CA19-9 while maintaining a high level of specificity. YiDiXie™ tests have an important diagnostic value in colorectal cancer, and are expected to solve the problems of "high false-positive rate" and "high false-negative rate" of FOBT, CEA, CA125 and CA19-9. Clinical trial number: ChiCTR2200066840. Key words: Colorectal cancer, Fecal occult blood test, CEA, CA125, CA19-9, False-positive, False-negative, YiDiXie™-SS, YiDiXie™-HS, YiDiXie™-D